Ipinzan

Metformin Hydrochloride / Vildagliptin, the active ingredient in Ipinzan, is a Biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients.

GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipinzan is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring long‑term glucose control.

Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c levels. Adjunct to diet and exercise: improves overall glycaemic management when lifestyle measures are insufficient. Combination therapy with other antidiabetics: provides additional glucose‑lowering effect in patients not achieving targets with a single agent.

Ipinzan may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nausea - Diarrhoea - Abdominal discomfort - Headache - Dizziness - Metallic taste

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycaemia (especially with insulin or sulfonylureas) - Acute pancreatitis - Hepatic dysfunction - Allergic reactions such as rash or angioedema - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating Ipinzan, several safety considerations should be addressed.

Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. Hepatic function monitoring: check liver enzymes periodically. Risk of lactic acidosis: educate patients about symptoms and contraindications. Hypoglycaemia monitoring: especially when combined with insulin or sulfonylureas. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at room temperature: keep in original container, protect from moisture and light.

Ipinzan can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Iodinated contrast agents: potential for acute renal dysfunction. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - NSAIDs: can impair renal function, increasing metformin exposure.